Aspen Pharmacare Holdings Ltd
$
7.17
0.02 (0.28%)
| Volume: | 8,976 | Avg Vol (1m): | 22,646 |
| Market Cap $: | 3.35 Bil | Enterprise Value $: | 7.08 Bil |
| P/E (TTM): | 8.79 | P/B: | 0.91 |
| Earnings Power Value | 2.34 |
| Net Current Asset Value | -5.56 |
| Tangible Book | -3.44 |
| Projected FCF | 8.55 |
| Median P/S Value | 23.36 |
| Graham Number | 0 |
| Peter Lynch Value | 9.52 |
| DCF (FCF Based) | -0.26 |
| DCF (Earnings Based) | 20.23 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.16 |
Cash-To-Debt ranked
lower than
85.56%
of
859
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
APNHY:
0.16
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.16, Med: 0.32, Max: 128.44
Current: 0.16
|
| Equity-to-Asset | 0.39 |
Equity-to-Asset ranked
lower than
82.36%
of
788
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
APNHY:
0.39
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.31, Med: 0.4, Max: 0.55
Current: 0.39
|
| Debt-to-Equity | 1.21 |
Debt-to-Equity ranked
lower than
86.91%
of
596
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
APNHY:
1.21
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.88, Max: 1.55
Current: 1.21
|
| Debt-to-EBITDA | 6.87 |
Debt-to-EBITDA ranked
lower than
81.01%
of
495
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
APNHY:
6.87
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: 2.14, Med: 3.64, Max: 6.87
Current: 6.87
|
| Interest Coverage | 4.25 |
Interest Coverage ranked
lower than
83.49%
of
648
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
APNHY:
4.25
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 3.11, Med: 4.86, Max: 5.98
Current: 4.25
|
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 1.41 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.44 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 8.56%
WACC 8.98%
| ||
Profitability & Growth : 8/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 24.07 |
Operating Margin ranked
higher than
82.40%
of
801
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
APNHY:
24.07
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: 23.27, Med: 25.6, Max: 28.65
Current: 24.07
|
| Net Margin % | 12.40 |
Net Margin ranked
higher than
76.18%
of
802
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
APNHY:
12.4
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: 12.08, Med: 16.51, Max: 20.82
Current: 12.4
|
| ROE % | 10.85 |
ROE ranked
higher than
75.24%
of
832
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
APNHY:
10.85
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: 10.85, Med: 17.97, Max: 36.01
Current: 10.85
|
| ROA % | 4.08 |
ROA ranked
higher than
60.96%
of
871
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
APNHY:
4.08
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: 4.08, Med: 8.48, Max: 12.24
Current: 4.08
|
| ROC (Joel Greenblatt) % | 35.21 |
ROC (Joel Greenblatt) ranked
higher than
87.60%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
APNHY:
35.21
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: 32.99, Med: 49.85, Max: 79.26
Current: 35.21
|
| 3-Year Total Revenue Growth Rate | 5.70 |
3-Year Revenue Growth Rate ranked
higher than
69.81%
of
689
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 291.9, Med: 5.8, Min: -100
APNHY:
5.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 5.7, Med: 22.6, Max: 33.4
Current: 5.7
|
| 3-Year Total EBITDA Growth Rate | 3.30 |
3-Year EBITDA Growth Rate ranked
lower than
56.82%
of
704
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
APNHY:
3.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 2, Med: 24.1, Max: 46.5
Current: 3.3
|
| 3-Year EPS w/o NRI Growth Rate | 4.90 |
3-Year EPS w/o NRI Growth Rate ranked
lower than
62.29%
of
663
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
APNHY:
4.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0.8, Med: 26, Max: 365.5
Current: 4.9
|
» APNHY's 30-Y Financials
Financials
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with OTCPK:APNHY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Drug Manufacturers » Drug Manufacturers - Specialty & Generic |
| Compare | SZSE:000513 TSE:4527 SZSE:000623 XCNQ:GTII XCNQ:CURA TSE:4530 LIM:BAYERI1 NSE:ALKEM XTER:EVT HKSE:02005 SHSE:600277 SHSE:600511 BUD:RICHTER NYSE:AMRX BOM:532296 SHSE:600521 HKSE:00460 SHSE:603707 SZSE:002038 SZSE:000999 |
| Traded in other countries | LDZA.Germany APN.South Africa |
| Address | Woodlands Drive, Woodmead, PO Box 1587, Gallo Manor, Building Number 8, Healthcare Park, Johannesburg, ZAF, 2052 |
| Aspen Pharmacare Holdings Ltd is a specialty and generic drug manufacturing company. The company maintains a focus on four therapeutic categories: thrombosis, anaesthetics, high potency and cytotoxics, and infant nutritionals. Aspen generates the vast majority of its revenue through its commercial-pharma segment, followed by manufacturing and commercial-nutritionals segments. The company considers potential merger and acquisition investment a component of its operational growth strategy to expand its research, development, manufacturing, and marketing capabilities. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 9.05 |
PE Ratio ranked
higher than
64.63%
of
557
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
APNHY:
9.05
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 6.92, Med: 23.07, Max: 40.2
Current: 9.05
|
| PE Ratio without NRI | 8.79 |
PE without NRI ranked
higher than
66.01%
of
556
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
APNHY:
8.79
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 6.92, Med: 23.98, Max: 40.2
Current: 8.79
|
| Price-to-Owner-Earnings | 12.59 |
Price-to-Owner-Earnings ranked
lower than
58.95%
of
324
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
APNHY:
12.59
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 10.92, Med: 43.44, Max: 132.77
Current: 12.59
|
| PB Ratio | 0.91 |
PB Ratio ranked
lower than
50.43%
of
819
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
APNHY:
0.91
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0.83, Med: 3.89, Max: 7.5
Current: 0.91
|
| PS Ratio | 1.13 |
PS Ratio ranked
higher than
52.13%
of
775
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
APNHY:
1.13
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 0.98, Med: 3.67, Max: 6.78
Current: 1.13
|
| Price-to-Operating-Cash-Flow | 6.83 |
Price-to-Operating-Cash-Flow ranked
higher than
59.69%
of
392
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
APNHY:
6.83
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.93, Med: 22.62, Max: 54.21
Current: 6.83
|
| EV-to-EBIT | 10.99 |
EV-to-EBIT ranked
higher than
52.45%
of
572
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
APNHY:
10.99
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: 9.1, Med: 18.4, Max: 29.5
Current: 10.99
|
| EV-to-EBITDA | 10.99 |
EV-to-EBITDA ranked
lower than
55.95%
of
597
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
APNHY:
10.99
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 8.3, Med: 17, Max: 26.7
Current: 10.99
|
| EV-to-Revenue | 2.38 |
EV-to-Revenue ranked
lower than
53.71%
of
795
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
APNHY:
2.38
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 4.4, Max: 7.8
Current: 2.38
|
| PEG Ratio | 0.75 |
PEG Ratio ranked
higher than
67.19%
of
317
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
APNHY:
0.75
Ranked among companies with meaningful PEG Ratio only.
|
PEG Ratio range over the past 10 years
Min: 0.37, Med: 1.06, Max: 2.09
Current: 0.75
|
| Shiller PE Ratio | 11.71 |
Shiller PE Ratio ranked
lower than
51.19%
of
252
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
APNHY:
11.71
Ranked among companies with meaningful Shiller PE Ratio only.
|
Shiller PE Ratio range over the past 10 years
Min: 10.15, Med: 50.95, Max: 91.03
Current: 11.71
|
| Current Ratio | 2.05 |
Current Ratio ranked
lower than
89.94%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
APNHY:
2.05
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.7, Med: 1.4, Max: 2.05
Current: 2.05
|
| Quick Ratio | 1.34 |
Quick Ratio ranked
lower than
91.93%
of
855
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
APNHY:
1.34
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.49, Med: 0.96, Max: 1.34
Current: 1.34
|
| Days Inventory | 252.95 |
Days Inventory ranked
lower than
84.77%
of
755
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
APNHY:
252.95
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 115.22, Med: 150.76, Max: 259.83
Current: 252.95
|
| Days Sales Outstanding | 113.90 |
Days Sales Outstanding ranked
lower than
73.77%
of
770
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
APNHY:
113.9
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 79.88, Med: 92.21, Max: 113.9
Current: 113.9
|
| Days Payable | 162.35 |
Days Payable ranked
higher than
79.55%
of
758
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
APNHY:
162.35
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 72.18, Med: 118, Max: 162.35
Current: 162.35
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| Dividend Yield % | 2.95 |
Trailing Dividend Yield ranked
lower than
62.77%
of
752
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
APNHY:
2.95
Ranked among companies with meaningful Trailing Dividend Yield only.
|
Trailing Dividend Yield range over the past 10 years
Min: 0.36, Med: 0.72, Max: 3.15
Current: 2.95
|
| Dividend Payout Ratio | 0.25 |
Dividend Payout Ratio ranked
higher than
65.83%
of
477
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 68, Med: 0.3, Min: 0.02
APNHY:
0.25
Ranked among companies with meaningful Dividend Payout Ratio only.
|
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.19, Max: 0.25
Current: 0.25
|
| 3-Year Dividend Growth Rate (Per Share) | 15.10 |
3-Year Dividend Growth Rate ranked
higher than
72.91%
of
299
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 114, Med: 7.4, Min: -100
APNHY:
15.1
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
|
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 15.1, Max: 63.4
Current: 15.1
|
| Forward Dividend Yield % | 2.97 |
Forward Dividend Yield ranked
lower than
66.48%
of
719
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
APNHY:
2.97
Ranked among companies with meaningful Forward Dividend Yield only.
| N/A |
| Yield-on-Cost (5-Year) % | 5.63 |
Yield-on-Cost (5y) ranked
higher than
59.60%
of
745
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
APNHY:
5.63
Ranked among companies with meaningful Yield-on-Cost (5y) only.
|
Yield-on-Cost (5y) range over the past 10 years
Min: 0.69, Med: 1.37, Max: 6.01
Current: 5.63
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 0.84 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
100.00%
of
374
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 209, Med: 2.11, Min: 0.05
APNHY:
0.84
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.84, Med: 3.61, Max: 5.84
Current: 0.84
|
| Price-to-DCF (Earnings Based) | 0.35 |
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked
higher than
86.36%
of
110
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
APNHY:
0.35
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
|
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.79, Med: 1, Max: 1.35
Current: 0.35
|
| Price-to-Median-PS-Value | 0.31 |
Price-to-Median-PS-Value ranked
lower than
100.00%
of
743
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
APNHY:
0.31
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.31, Med: 0.9, Max: 1.46
Current: 0.31
|
| Price-to-Peter-Lynch-Fair-Value | 0.75 |
Price-to-Peter-Lynch-Fair-Value ranked
lower than
100.00%
of
212
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
APNHY:
0.75
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
|
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.54, Med: 1.25, Max: 1.85
Current: 0.75
|
| Earnings Yield (Joel Greenblatt) % | 9.10 |
Earnings Yield (Greenblatt) ranked
higher than
68.63%
of
867
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
APNHY:
9.1
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.4, Med: 5.4, Max: 11
Current: 9.1
|
| Forward Rate of Return (Yacktman) % | 13.01 |
Forward Rate of Return ranked
higher than
76.96%
of
421
companies
in the
Drug Manufacturers - Specialty & Generic
industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
APNHY:
13.01
Ranked among companies with meaningful Forward Rate of Return only.
|
Forward Rate of Return range over the past 10 years
Min: 11.5, Med: 20, Max: 22
Current: 13.01
|
More Statistics
| Revenue (TTM) (Mil) $ | 3,113.91 |
| EPS (TTM) $ | 0.84 |
| Beta | 1.06 |
| Volatility % | 57.5 |
| 52-Week Range $ | 6.01 - 21.16 |
| Shares Outstanding (Mil) | 456 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |